ABSTRACT. Antioxidant properties of bisulfite are used i to stabilize parenteral amino acid solutions. After reports of adverse reactions to dietary sulfites, we evaluated whether the infusion of bisulfite had biologic effects on human vascular tissue. Because an endothelial oxidative injury can affect mediators ot vasoreactivity, vascular pressure and prostaglandin production were studied in an intact human vein model infused with clinically relevant amino acid solutions differing only by their metabisulfite content (0 versus 300 mg/L). The amino acid solution containing bisulfite presented higher venous pressure ( p < 0.01) and prostaglandin production (6-keto-prostaglandin FIR, p < 0.01; and prostaglandin E2, p < 0.05). A hydroxyl radicalgenerating system added to the solutions did not modify the pressure readings, but it resulted in an overall decrease in prostacyclin production ( p < 0.05). Despite this known inhibitory effect on oxidative challenge on prostaglandin I2 production, prostaglandins remained higher in the presence of bisulfite. The results suggest that the effect of bisulfite takes place before prostaglandin H 2 synthesis in the eicosanoid cascade, whereas the oxidative challenge affects
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Sulfites are widely used in food processing and in the pharmaceutical industry: these additives have antimicrobial properties. prevent fermentation as well as food discoloration. and exert antioxidant properties (I after ingestion of metabisulfite could be IgE-mediated (3), as these clinical manifestations were present mainly in patients with a history of hypersensitivity. The exact mechanism of sulfite-induced reactions remains unclear (4) and is still under investigation (5).
-.
B~suifite, which is present in severai parenterai amino acid solutions used in neonatology, pediatrics, and adult medicine, is added during the manufacturing process to ensure stability during and after sterilization. After enteral alimentation, the sulfite is transformed in the liver by sulfite oxidase to a sulfate, which forms strong complexes with calcium ion and is eliminated in the urine (6) . However, during parenteral nutrition, the bisulfite could exert a vascular action close to the site of infusion, before its transformation by the liver enzyme. Because of the adverse reactions to bisulfites in foods. methods were developed to manufacture parenteral amino acid solutions without bisulfite. This presented us with the opportunity to address the biologic effects of bisulfite on human tissue.
Solutions of i.v. alimentation produce specific vascular responses at the site of infusion (7) . stressing the importance of vasoactive endothelial mediators and their relation to i.v. therapies such as parenteral nutrition. The bisulfite used to stabilize parenteral amino acid solutions (8) was suspected to interfere with the vasoactive mediators. An array of vasoactive biochemical factors has been described (9-15), several of these factors act at the site of endothelial production, such as the eicosanoids (10) . Prostaglandins are mediators that could be affected by antioxidant properties of bisulfite, inasmuch as the synthesis of prostaglandins is inhibited by oxidants such as peroxides and oxygen radicals (16) (17) (18) .
The objective of this study was to determine whether bisulfite infused with amino acid solutions influenced the local prostaglandin production and the venous tone in a human vascular model designed to study the local effects of parenteral nutrition. Prostaglandins from the endothelial membrane (PGI*) and the cytoplasm (PGE2) were measured to determine more closely the site of action of bisulfite. mmol/L NaHC03, amino acid solutions, and water plus electrolytes (Na, 7.5 mmol; K, 6.0 mmol; C1, 7.5 mmol; Ca, 5.0 mmol: Mg, 0.3 1 mmol; SOa, 0.3 1 mmol; and acetate, 13.7 mmol). The amino acid solutions differed only in their metabisulfite (Na2S205) content; Blend C (Travasol 10% Blend C amino acid solution: Clintec Nutrition, Mississauga, Ontario, Canada) contained 300 mg metabisulfite/L and TIV (Travasol 10% Blend C amino acid solution in Viaflex; Clintec Nutrition) was devoid of metabisulfite. It was verified that the amino acid profile of Blend C (1 9) was comparable to that of TIV. Furthermore, an oxidative challenge was added to the studied solutions, as a hydroxyl radical-generating system (10 mmol/L H202 + 0.2 mmol/L FeC12) (20) .
Experimental Design. Three series of measurements were undertaken comparing I ) Blend C versus TIV in six umbilical veins; 2) Blend C versus Blend C + hydroxyl radical in six additional veins; and 3) TIV versus TIV + hydroxyl radical in another six veins. Each solution of a pair was randomly assigned to two adjacent samples of the same length from a cord. In pilot studies, no relationships had been found between the site of umbilical cord section (proximity of the sample to the placenta) and the 6-keto-PGF,, production or the pressure.
Within 0.5 h of birth, the vein was infused during 15 min with a flow rate set at 200 mL/h to wash out residual blood; thereafter. the flow was maintained at a constant rate of 20 mL/h. At 20 n~L/h, the di:uf oii of prostaglandins was such that PGE2 and 6-keto-PGF,, concentrations were above the threshold of detection and therefore directly measurable in the perfusate. Each aliquot of perfusate (0.9 mL) was sampled at the distal end of the vein at 0.5, 1.5, 2.5, and 3.5 h of infusion, mixed with 0.1 mL Analytical Procedures. Prostaglandins. PGE2 and 6-keto-PGF,, (the stable metabolite of PG12) were measured directly on the sample by RIA using the antisera from Advanced Magnetics Inc. (Cambridge, MA). The technique used was proposed by the company. Briefly, after 2 h of incubation at 25°C with the antisera, the free 'H-tracer was separated by charcoal-dextran precipitation. An aliquot of the supernatant, reflecting the bound fraction, was counted. To verify whether the assay measured only prostaglandins, samples were measured before and after extraction on a reverse-phase Sep-Pack column (Waters Associates, Milford, MA) (2 1). For both prostaglandins. there was over 90% recovery. The cross-reactivities at half of Bo/T (bound in zero standard/ total count) for antiscra against 6-kcto-PGF,, cvcrc 6-kcto-PGE, = 6.8%, PGF2, = 2.2%, and PGE2 = 0.6%: for antisera against PGE2 they were PGE, = 50%, PGF*, = 1.3%. and 6-keto-PGF,, = 0.1%. The levels of detection within a 95% confidence limit were 0.20 ng/mL (pg/L) for 6-keto-PGF,, and 0.34 ng/mL (pg/ L) for PGE2. The intraassay coefficient of variation was 4%. and the interassay variation was 15%.
The pressure generated by the vessel was measured at the proximal end with a water column and changes from baseline were recorded.
Cellular 1,rahilitj-. The endothelial cells were isolated according to the method of Jaffe et 01. (22) . The cells from 5 cm of the vein were isolated after incubation with 0.2% (wt/vol) collagenase (CLS. Worthington Biochemical Corporation. Freehold. NJ) for 15 min at 37°C. The cellular viability was determined by counting on a hemocytometer, using the method of exclusion of trypan blue (0.1 % in cellular suspension).
Lipoprotein lipase. The activity was measured in sitzr. Two pmol/L of the substrate glycerol tri[l-'4C]oleate (Amersham. Oakville. Ontario, Canada) were directly incubated in the vein: 0.5 mL of substrate was incubated in 8 cm of vein for 90 min. The enzyme was measured according to Nilson-Ehle and Schotz (23) .
Statistical .4na/j9sis. The effects of time and treatments were Tables 1 and 2 .
RESULTS
The functional integrity of the endothelial cells was tested at the time of preparation of the model by measuring the cellular viability (mean f SEM. 91 f 3%. n = 6). and the activity of the lipoprotein lipase: that activity (10.0. 1.6, and 2.3 pmol/90 min) was in the same order of magnitude as levels found in human placenta on the fetal side (24) .
The results presented in Figures 1 through 3 show separate effects of time and treatments: the statistical analysis is presented in Table 1 . Although the duration of the infusion significantly affected the synthesis of PG12. time did not interfere with the pressure readings (Fig. 4. Table 2) .
The productions of 6-keto-PGFI, (Fig. 1) and PGE2 (Fig. 2 ) were higher with Blend C (with bisulfite). To determine whether LAVOIE AND CHESSEX this prostaglandin stimulation by bisulfite was related to its effect on oxidants present in the oxygenated medium, the studied solutions were additionally challenged with the hydroxyl radical (Fig. 3) . In both solutions, this oxidative stress inhibited the 6-keto-PGF,, production: however, the values remained higher with Blend C. The significant increase in PGE2 due to the hydroxyl radical was observed only with Blend C; the statistical analysis of the interaction between treatment and time (Table 1 ) showed that the effect of the hydroxyl radical on PGE2 production in Blend C was affected by time, as well. The results from Figure 3B suggest that the effect of the hydroxyl radical on this eicosanoid occurred early in the infusion. The venous tone was greater during the infusion of the bisulfite-containing solution (Fig. 4) . In this model, we could find no correlation between changes in pressure and PC12 or PGE2 production. Furthermore, the inhibition of prostacyclin by the hydroxyl radical was not reflected in the pressure readings (Fig. 5) . These results document that bisu~fite had biologic effects on prostaglandins as well as on vascular tone. DISCUSSION This study demonstrates that the bisulfite used in parenteral nutrition modifies local vasoreactivity. This finding is of importance because sulfites are widely used additives in drugs and in nutrition to prevent oxidative-induced degradation.
The similarity of values obtained in repeat experiments with TIV and Blend C (Figs. I and 2 versus Fig. 3 ) underlines the reproducibility of the data and therefore the reliability of the model. Although the physiologic flow rate in the human umbilical cord is about 7.3 L/h/kg (25), it was not practical to mimic this flow rate in the laboratory. The experimental flow was chosen to obtain a pressure reading and levels of prostaglandins directly measurable in the perfusate. The effect of time is to be considered separately from the effect of bisulfite, because it appears that the source of variation due to time is inherent in the model. Indeed, the overall decrease in 6-keto-PGF,, over time was similar to the prostaglandin response found in the abdominal a0rt.a of the rat, infused at a similar flow rate (26) . The initially elevated prostacyclin production could be related to the manipulations required to prepare the vessel (26) . However, this does not explain why PGE2 was not affected.
Because oxidants inhibit the synthesis of prostaglandins (16) (17) (18) . one could interpret the stimulatory effects of bisulfite on prostaglandins (Figs. I and 2) as a protection against oxidants present in the studied solutions.To verify this hypothesis. the solutions were challenged with a system known to generate oxygen-reactive substances (20) . which are present after reperfusion with oxygenated solutions (16) . The expected response to the oxidative challenge was a decrease in prostaglandin production ( I 6-18) with both amino acid solutions (Fig. 3) because the antioxidant capacity of bisulfite in Blend C should be overloaded by the 40-times-higher molar concentration of peroxide used for this challenge. Despite the significant decrease in 6-keto-PGF,,, induced by the addition of the hydroxyl radical to Blend C. the level of 6-keto-PGF,, was still twice as high as that observed with TIV. which is devoid of bisulfite (Fig. 3) . The statistical analysis demonstrates that for 6-keto-PGF,,,, there is no interaction between bisulfite and this oxidative challenge. Therefore, the persistence of a stimulatory effect of bisulfite on prostaglandins despite an oxidative challenge (Fig. 3) underlines that bisulfite has biologic effects that are separate from its antioxidant properties.
This effect of bisulfite has to take place before PGH2 synthesis in the eicosanoid cascade because it affects PC12 as well as PGE2. On the other hand, the free oxygen radical has an inhibitory effect on prostacyclin synthase (27) as supported by the results of Fig. 3'4 . This would explain why the hydroxyl radical-enriched system leads to an increase in PGE2 only when stimulated by bisulfite. as the availabilitv of PGH7 is increased bv both bisulfite and the oxidative challe&e, the latter inhibit& the further conversion of PGH2 to PG12.
Even though the endothelium, which produces the prostagl~n-dins, represents an important body compartment, one should be cautious in extrapolating the vascular effects of bisulfite to other organs, tissues, or species. Clyman el al. (28) reported different effects of reactive oxygen metabolites on the pulmonary circulation in the lamb and the rabbit. Physiologic differences also exist between vessels of the same species (29) . Furthermore, the changes in PC12 and PGE2 did not account for the variations in vascular tone, which is not surprising, considering the many other endothelial mediators such as endothelium-derived relaxing factor (30) and endothelin (3 I).
In a variety of food products. bisulfite is used for the purpose of manufacturing stability, not for biologic or clinical reasons. We show here that parenteral bisulfite has biologic effects. Although the vasoreactivity induced by bisulfite was statistically documented. the clinical significance of these findings must be carefully evaluated. In view of the general willingness to eliminate sulfites from the diet, one should verify that the biologic effects outweigh the antioxidant properties before removing this additive or replacing it with another antioxidant.
